By application of a clinical proteomics approach, our study demonstrates that small serum proteins such as Hp-α1, Hp-α2, VDBP and ApoC-III may serve as valid predictors for etanercept drug response in RA. The gene discussed is APOC3; the disease is rheumatoid arthritis.